Recent Updates
Recently added Catalysts
IBRX Positive Sentiment Score: 85/100

ImmunityBio Reports Record Q1 2026 Results: Net Product Revenue Increased Nearly 2.7x Year-Over-Year to $44 Million in Q1 2026 Expanding on the 2025 Full Year 700% Year-Over-Year Revenue Growth; Cash and Marketable Securities Total $381 Million

Thursday, May 7, 2026 1 min read
Key Takeaway: ImmunityBio reported impressive financial results for Q1 2026, with net product revenue reaching approximately $44.2 million, marking a 168% increase compared to Q1 2025. This growth reflects a consistent upward trend since the commercial launch of ANKTIVA. The company also reported a robust cash position of $381 million.

Market Sentiment Analysis

POSITIVE FACTORS

  • Record net product revenue of $44.2 million in Q1 2026.
  • Revenue increased nearly 2.7 times year-over-year.
  • Consistent growth in net product revenue since ANKTIVA's launch.
  • Strong financial position with $381 million in cash and marketable securities.

Full Press Release Details

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a biotechnology company, announced financial and operational highlights for the fiscal quarter ended March 31, 2026. The Company reported net product revenue of approximately $44.2 million during the three months ended March 31, 2026, with net product revenue growth in every quarter since ANKTIVA’s commercial launch, including a 168% increase over Q1 2025. This builds on full-year 2025 net product revenue of $113.0 million,

Frequently Asked Questions

What was ImmunityBio's net product revenue for Q1 2026?

ImmunityBio reported net product revenue of approximately $44.2 million for Q1 2026.

How much did revenue increase year-over-year?

The revenue increased nearly 2.7 times year-over-year, with a 168% rise over Q1 2025.

What was the total cash and marketable securities for ImmunityBio?

ImmunityBio reported total cash and marketable securities of $381 million.

What product's launch contributed to revenue growth?

The revenue growth is attributed to the commercial launch of ANKTIVA.

Tags: IBRX Viatris Investor Conferences Healthcare ImmunityBio ANKTIVA revenue growth financial results
Last updated: May 7, 2026